Clinical Trial Update: MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MS-275 (entinostat) in combination with GM-CSF in adults with myelodysplastic syndromes and/or relapsed or refractory acute myeloid leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• MS-275 (entinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 2 | Status: COMPLETED | Results posted: 2017-04-17